PAIGE
LIVE

Serial Number

88308511

Owner

PAIGE.AI, Inc.

Attorney

Mark Leonardo

First Use Date

Feb 21, 2019

Filing Date

Feb 20, 2019

Add to watchlist:

No watchlists yet
View on USPTO

PAIGE Trademark

Serial Number: 88308511 • Registration: 6206397

PAIGE is a trademark filed by PAIGE.AI, Inc. on February 20, 2019. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

PAIGE.AI, Inc. (12 trademarks)

New York, NY 10036

Entity Type: 03

Trademark Details

Filing Date

February 20, 2019

Registration Date

November 24, 2020

First Use Anywhere

February 21, 2019

First Use in Commerce

February 21, 2019

Published for Opposition

July 2, 2019

Goods & Services

Medical services; cancer therapy services; medical testing, namely, the review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseases, states, or conditions; medical testing for evaluation of prognosis relating to diseases, states, or conditions; medical testing for the monitoring of diseases, states, or conditions; medical testing to detect or identify predispositions to diseases, states, or conditions; medical testing to detect or determine the recurrence of diseases, states, or conditions; medical testing to detect, monitor, or evaluate responses to treatment of diseases, states, or conditions; medical testing to evaluate clinical management of diseases, states, or conditions; medical testing for selection of treatment for diseases, states, or conditions; medical testing to evaluate or facilitate prevention of diseases, states, or conditions; medical testing to select, facilitate, monitor, or evaluate palliation or treatment of diseases, states or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testing, monitoring, or reporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseases, states, or conditions; medical analysis or advisory services for the evaluation of prognosis relating to diseases, states, or conditions; medical analysis or advisory services relating to monitoring diseases, states, or conditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseases, states, or conditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseases, states, or conditions; medical analysis or advisory services relating to the detection, monitoring, or evaluation of responses to treatment of diseases, states, or conditions; medical analysis or advisory services relating to the clinical management of diseases, states, or conditions; medical analysis or advisory services relating to the selection of treatment for diseases, states, or conditions; medical analysis or advisory services relating to the prevention of diseases, states, or conditions; medical analysis or advisory services relating to the palliation or treatment of diseases, states or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slides

Software as a service (SaaS) services featuring software for artificial intelligence, machine learning, deep learning, statistical learning, data mining, and contextual prediction; software as a service (SaaS) services featuring software for use in disease pathology, namely, software that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseases, states, or conditions; software as a service (SaaS) services featuring software for use in monitoring of diseases, states, or conditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseases, states, or conditions; software as a service (SaaS) services featuring software to detect the recurrence of diseases, states, or conditions; software as a service (SaaS) services featuring software to detect, monitor, or evaluate patients' responses to treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in clinical management of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in prevention of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposes

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jun 17, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 17, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 17, 2026 REAP
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Mar 4, 2026 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Mar 4, 2026 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 4, 2026 APRE
TEAS SECTION 8 & 15 RECEIVED
Dec 1, 2025 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Nov 24, 2025 REM1
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jan 29, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 29, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 29, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 29, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 29, 2021 COAR
REGISTERED-PRINCIPAL REGISTER
Nov 24, 2020 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Oct 22, 2020 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 21, 2020 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 21, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2020 CRFA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 13, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 13, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 13, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 13, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 13, 2020 COAR
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 13, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 11, 2020 GNRN
NON-FINAL ACTION E-MAILED
Sep 11, 2020 GNRT
SU - NON-FINAL ACTION - WRITTEN
Sep 11, 2020 CNRT
STATEMENT OF USE PROCESSING COMPLETE
Aug 13, 2020 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 12, 2020 AITU
USE AMENDMENT FILED
Jul 31, 2020 IUAF
TEAS STATEMENT OF USE RECEIVED
Jul 31, 2020 EISU
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 8, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 8, 2020 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 8, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 8, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 8, 2020 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 24, 2020 EXRA
SOU EXTENSION 1 GRANTED
Apr 22, 2020 EX1G
SOU EXTENSION 1 FILED
Apr 22, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 22, 2020 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 22, 2019 NOAM
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Sep 11, 2019 ETOP
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 14, 2019 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 14, 2019 REAP
EXTENSION OF TIME TO OPPOSE RECEIVED
Jul 31, 2019 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 2, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jul 2, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 12, 2019 NONP
ASSIGNED TO LIE
May 29, 2019 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
May 15, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
May 15, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 15, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
May 15, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 15, 2019 CNEA
ASSIGNED TO EXAMINER
May 1, 2019 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 12, 2019 NWOS
NEW APPLICATION ENTERED
Feb 23, 2019 NWAP